BAY 3547926

BAY 3547926 is an investigational radiopharmaceutical drug developed by Bayer for the treatment of advanced hepatocellular carcinoma (HCC), a type of liver cancer. The drug works by delivering a radioactive agent directly to cancer cells, specifically targeting them and emitting radiation that damages and kills these cells while minimizing harm to surrounding healthy tissue. This targeted approach is designed to maximize anti-tumor effects with reduced systemic toxicity. The mechanism involves the use of a radioactive payload, and it may target glypican-3 (GPC3), which is commonly overexpressed in HCC cells. As of now, BAY 3547926 is being evaluated in its first-in-human Phase 1 clinical trial to determine its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced HCC.